Clin Gastroenterology H: Long-term obenic cholicacid therapy improves histological endpointining in patients with primary bile ductitis

Background and objective: Primary bile-borne bile ductitis (PBC) is an autoimmune disease characterized by the destruction of the bile duct swells and the potential for the development of cirrhosisThis study was conducted in the PBC Ocabecholic acid (OCA) International TherapeuticSis Study (POISE) liver biopsy to determine the long-term effects of OCA on liver damage and fibrosis in PBC patientsmethod: Researchers collected liver biopsy samples in 17 patients during the double-blind period and 3 years after OCA treatmentA hetological assessment was conducted in a blind, random manner by two pathologists to determine the effects of OCA on fibrosis and other tissue parametersThe collagen morphological measurements are measured by automatic secondary harmonic generation and 2 photon excitation microscopes to observe quantitative measurements of fibrosisresults: Most patients have improved or stabilized with fibrosis (71%), bile duct loss (76%), bile duct reduction (82%), catheter response (82%), and interface hepatitis (100%) from intake to 3 years of treatmentOver a three-year period, the researchers found that the collagen area ratio (median -2.1; the first quartile was -4.6; the third quartile was -0.3; p-0.013), and the collagen fiber density (median was -0.8; the first quartile, -2.5; the third quartile, 0; p.The collagen mesh index (median, -0.1; first quartile, -0.3; third quartile, 0; PConclusion: This study shows that long-term use of OCA in Patients with PBC is associated with improvement or stabilization of disease characteristics, including catheter damage, fibrosis, and collagen morphological characteristics